Application of Anti-Methotrexate Fab Fragments for the Optimization of Intraperitoneal Methotrexate Therapy in a Murine Model of Peritoneal Cancer
- 1 September 2005
- journal article
- research article
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 94 (9) , 1957-1964
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Development and Validation of Enzyme‐Linked Immunosorbent Assays for Quantification of Anti‐Methotrexate IgG and Fab in Mouse and Rat PlasmaJournal of Immunoassay and Immunochemistry, 2004
- Application of Pharmacokinetic–Pharmacodynamic Modeling to Predict the Kinetic and Dynamic Effects of Anti-Methotrexate Antibodies in MiceJournal of Pharmaceutical Sciences, 2003
- Pharmacokinetic–Pharmacodynamic Modeling of Methotrexate-Induced Toxicity in MiceJournal of Pharmaceutical Sciences, 2003
- Protection against Lipopolysaccharide-Induced Death by FluoroquinolonesAntimicrobial Agents and Chemotherapy, 2000
- Management of peritoneal and hepatic metastases from gastrointestinal stromal tumorsSurgical Oncology, 2000
- Intraperitoneal Cisplatin plus Intravenous Cyclophosphamide versus Intravenous Cisplatin plus Intravenous Cyclophosphamide for Stage III Ovarian CancerNew England Journal of Medicine, 1996
- Inverse Targeting of Peritoneal Tumors: Selective Alteration of the Disposition of Methotrexate Through the Use of Anti-Methotrexate Antibodies and Antibody FragmentsJournal of Pharmaceutical Sciences, 1996
- Colorectal cancer and peritoneal carcinomatosisSeminars in Surgical Oncology, 1996
- Intraperitoneal chemotherapy in the management of ovarian cancerCancer, 1993
- Efficacy of Two‐route Chemotherapy Using Intraperitoneal Neocarzinostatin and Its Antidote, Intravenous Tiopronin, for Peritoneally Disseminated Tumors in MiceJapanese Journal of Cancer Research, 1989